Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Albert Wiegman

Showing results (101-110 of 125) with videos related to

Pageof 13
Sort By:
The New England Journal of Medicine|September 1, 2020
Evolocumab in Pediatric Heterozygous Familial HypercholesterolemiaRaul D Santos, Andrea Ruzza, G Kees Hovingh, et al.
The Lancet. Diabetes & Endocrinology|September 8, 2022
Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCTRaul D Santos, Andrea Ruzza, G Kees Hovingh, et al.
European Heart Journal|February 10, 2025
Fibroblast growth factor 5: a novel biomarker for familial hypercholesterolaemiaAndrea Baragetti, Asiiat S Alieva, Liliana Grigore, et al.
Circulation|October 20, 2023
Evinacumab for Pediatric Patients With Homozygous Familial HypercholesterolemiaAlbert Wiegman, Susanne Greber-Platzer, Shazia Ali, et al.
Journal of Clinical Lipidology|December 22, 2015
Efficacy and safety of rosuvastatin therapy in children and adolescents with familial hypercholesterolemia: Results from the CHARON studyMarjet J A M Braamskamp, Gisle Langslet, Brian W McCrindle, et al.
Circulation|June 9, 2017
Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label)Marjet J A M Braamskamp, Gisle Langslet, Brian W McCrindle, et al.
European Heart Journal|May 18, 2026
Homozygous familial hypercholesterolaemia: insights from the Global HICC RegistryWillemijn A M Schonck, Janneke W C M Mulder, Marina Cuchel, et al.
The Lancet. Child & Adolescent Health|May 17, 2024
Cardiovascular outcomes in patients with homozygous familial hypercholesterolaemia on lipoprotein apheresis initiated during childhood: long-term follow-up of an international cohort from two registriesM Doortje Reijman, Tycho R Tromp, Barbara A Hutten, et al.
European Heart Journal|June 10, 2024
Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacyDaniel Gaudet, Susanne Greber-Platzer, Laurens F Reeskamp, et al.
Molecular Genetics and Metabolism|February 24, 2024
Breaking the chains of lipoprotein lipase deficiency: A pediatric perspective on the efficacy and safety of VolanesorsenBibiche den Hollander, Marion M Brands, Ilse J M Nijhuis, et al.
Pageof 13

Showing results (101-110 of 125) with videos related to

Sort By:
Pageof 13
The New England Journal of Medicine|September 1, 2020
Evolocumab in Pediatric Heterozygous Familial HypercholesterolemiaRaul D Santos, Andrea Ruzza, G Kees Hovingh, et al.
The Lancet. Diabetes & Endocrinology|September 8, 2022
Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCTRaul D Santos, Andrea Ruzza, G Kees Hovingh, et al.
European Heart Journal|February 10, 2025
Fibroblast growth factor 5: a novel biomarker for familial hypercholesterolaemiaAndrea Baragetti, Asiiat S Alieva, Liliana Grigore, et al.
Circulation|October 20, 2023
Evinacumab for Pediatric Patients With Homozygous Familial HypercholesterolemiaAlbert Wiegman, Susanne Greber-Platzer, Shazia Ali, et al.
Journal of Clinical Lipidology|December 22, 2015
Efficacy and safety of rosuvastatin therapy in children and adolescents with familial hypercholesterolemia: Results from the CHARON studyMarjet J A M Braamskamp, Gisle Langslet, Brian W McCrindle, et al.
Circulation|June 9, 2017
Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label)Marjet J A M Braamskamp, Gisle Langslet, Brian W McCrindle, et al.
European Heart Journal|May 18, 2026
Homozygous familial hypercholesterolaemia: insights from the Global HICC RegistryWillemijn A M Schonck, Janneke W C M Mulder, Marina Cuchel, et al.
The Lancet. Child & Adolescent Health|May 17, 2024
Cardiovascular outcomes in patients with homozygous familial hypercholesterolaemia on lipoprotein apheresis initiated during childhood: long-term follow-up of an international cohort from two registriesM Doortje Reijman, Tycho R Tromp, Barbara A Hutten, et al.
European Heart Journal|June 10, 2024
Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacyDaniel Gaudet, Susanne Greber-Platzer, Laurens F Reeskamp, et al.
Molecular Genetics and Metabolism|February 24, 2024
Breaking the chains of lipoprotein lipase deficiency: A pediatric perspective on the efficacy and safety of VolanesorsenBibiche den Hollander, Marion M Brands, Ilse J M Nijhuis, et al.
Pageof 13